Credit Suisse’s Atossa Therapeutics ATOS Stock Holding History

Credit Suisse’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,018	Closed	-$24K	–	3633
2021 Q4	$24K	Buy	+1,018	New	+$37.3K	﹤0.01%	4442

Other funds holding ATOS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Credit Suisse's ATOS Position: Q1 2022 in Review

Credit Suisse sold out of Atossa Therapeutics (ATOS) in Q1 2022, closing a stake of 1,018 shares — an estimated $24K sold.

Credit Suisse first reported a position in ATOS in Q4 2021 and held it in 1 quarter. The position peaked at $24K in Q4 2021. 83 funds tracked by Wall St. Rank hold ATOS as of Q1 2022.

Credit Suisse reported no remaining Atossa Therapeutics position as of Q1 2022 after selling out during the quarter.
Credit Suisse sold 1,018 Atossa Therapeutics shares in Q1 2022, an estimated $24K.
Credit Suisse first reported a position in Atossa Therapeutics in Q4 2021 and held it in 1 quarter.
Credit Suisse's Atossa Therapeutics position peaked at $24K in Q4 2021.
83 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2022.

Based on Credit Suisse's 13F filing for Q1 2022, filed 16 May 2022.